IP Library › Granted Patent US 9,133,166
Granted Patent B2
US 9,133,166 · App. 14/210,006 · Granted Sep 15, 2015

Histone demethylase inhibitors

Inventors: Toufike Kanouni (La Jolla, CA); Zhe Nie (San Diego, CA); Jeffrey Alan Stafford (San Diego, CA); James Marvin Veal (Apex, NC)
Assignee: QUANTICEL PHARMACEUTICALS, INC.
C07D401/14C07D401/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,133,166
App. No.
14/210,006
Granted
Sep 15, 2015
Kind
B2
Abstract

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

Claims (25)

1. A compound having the structure of Formula (II):

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is hydrogen, or C6-C10aryl;

R 2 is C1-C5alkyl, C3-C8cycloalkyl, C6-C10aryl, C3-C8cycloalkyl(C1-C5alkylene), or C6-C10ar(C1-C5alkylene);

R 3 is hydrogen;

R 4 is —CO 2 H, —CO 2 R 6 , —C(O)N(H)CN, or —C(O)N(H)OH;

each R 5 is independently hydrogen, C1-C5alkyl, C3-C8cycloalkyl, C6-C10aryl, C3-C8cycloalkyl(C1-C5alkylene), or C6-C10ar(C1-C5alkylene); and

R 6 is C1-C5alkyl.

2. The compound of claim 1 , wherein R 4 is —CO 2 H.

3. The compound of claim 1 , wherein R 4 is —CO 2 R 6 .

4. The compound of claim 1 , wherein R 4 is —C(O)N(H)CN.

5. The compound of claim 1 , wherein R 2 is C1-C5alkyl.

6. The compound of claim 1 , wherein R 2 is methyl.

7. The compound of claim 1 , wherein R 2 is C1-C5alkyl substituted with (C1-C5alkyl)-O—.

8. The compound of claim 1 , wherein R 2 is C1-C5alkyl substituted with (C1-C5alkyl) 2 N—.

9. The compound of claim 1 , wherein R 2 is C1-C5alkyl substituted with (C6-C10aryl)(C1-C5alkyl)amino.

10. The compound of claim 1 , wherein R 2 is C1-C5alkyl substituted with (C3-C8cycloalkyl)(C1-C5alkyl)amino.

11. The compound of claim 1 , wherein R 2 is C1-C5alkyl substituted with (C6-C10ar(C1-C5alkylene))(C1-C5alkyl)amino.

12. The compound of claim 1 , wherein R 2 is C1-C5alkyl substituted with (C3-C8cycloalkyl(C1-C5alkylene))(C1-C5alkyl)amino.

13. The compound of claim 1 , wherein R 1 is hydrogen.

14. The compound of claim 1 , wherein R 1 is C6-C10aryl.

15. The compound of claim 14 , wherein R 1 is phenyl optionally substituted with one or more groups selected from halogen, —OH, —OR 5 , —N(R 5 ) 2 , —CON(R 5 ) 2 , C1-C5alkyl, C2-C5alkynyl, C3-C8cycloalkyl, C6-C10aryl, C3-C8cycloalkyl(C1-C5alkylene), and (C6-C10ar(C1-C5alkylene).

16. The compound of claim 14 , wherein R 1 is phenyl optionally substituted with one or more groups selected from halogen, —OH, —OR 5 , C1-C5alkyl, and C3-C8cycloalkyl.

17. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2016
From: QUANTICEL PHARMACEUTICALS, INC.
To: CELGENE QUANTICEL RESEARCH, INC.
Reel/Frame 038399/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2014
From: NIE, ZHE; STAFFORD, JEFFREY ALAN; VEAL, JAMES MARVIN; KANOUNI, TOUFIKE
To: QUANTICEL PHARMACEUTICALS, INC.
Reel/Frame 032456/0023 →
Continuity (2)
Provisional Application 61783563 · Mar 14, 2013
Related Publication 20140275084A1 · Sep 18, 2014